February 06, 2026 09:25 ET | Source: Ernexa Therapeutics Inc. CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics…
February 06, 2026 16:01 ET | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix,…
February 06, 2026 16:01 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE)…
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge,…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…
February 06, 2026 17:17 ET | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…
February 06, 2026 19:00 ET | Source: Cannabix Technologies Inc. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…